NCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
35 trialsNCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03133221 2025-06-27
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
University of Maryland, Baltimore
Phase 2 Completed
NCT02457598 2025-06-17
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Gilead Sciences
Phase 1 Terminated
NCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03890289 2024-11-21
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT03151057 2024-03-12
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03257722 2024-02-28
PIL
Augusta University
Phase 1/2 Terminated
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02536300 2023-08-14
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences
Phase 3 Terminated
NCT02968563 2022-01-21
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02242045 2021-03-19
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 1 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02538614 2020-11-25
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Terminated
NCT01796470 2020-06-02
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT02739360 2020-03-04
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Gilead Sciences
Phase 4 Terminated
NCT01090414 2019-08-28
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Gilead Sciences
Phase 1/2 Terminated
NCT01539291 2019-08-20
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Gilead Sciences
Phase 3 Terminated
NCT01659021 2019-08-14
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01282424 2019-07-11
DELTA
Gilead Sciences
Phase 2 Completed
NCT01539512 2019-05-14
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 3 Completed
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT01306643 2018-11-19
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Gilead Sciences
Phase 1/2 Completed
NCT01393106 2018-11-19
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Gilead Sciences
Phase 2 Completed
NCT01980875 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT02044822 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Gilead Sciences
Phase 2 Terminated
NCT01203930 2018-11-16
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Gilead Sciences
Phase 2 Terminated
NCT01732913 2018-11-16
Yosemite
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT02439138 2017-01-11
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Terminated